Page 18 - Alkermes News Today

Alkermes plc (ALKS) has completed the separation of its oncology business into Mural Oncology plc, an independent, publicly traded company. Mural Oncology will begin regular way trading on the Nasdaq Global Market under the ticker MURA on Nov.

BioPharma

Mural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company’s lead product candidate – nemvaleukin alfa – being developed to treat a wide range of solid tumors – is currently in two potentially registrational clinical trials, both with readouts expected in 1Q 2025 Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12 with plans to nominate a development...

In this piece, we will take a look at the 12 biggest healthcare stocks in Jim Simons stock portfolio.

KCSA appoints Alessandra Nagy as SVP. From PR Week

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conference...

Q3 2023 YUPELRI® net sales, recognized by Viatris, increased 9% from Q3 2022, reaching an all-time high of $58.3 million1Progress made towards the achievement of non-GAAP profitability, with Q3...

StockNews.com cut shares of Alkermes (NASDAQ:ALKS – Free Report) from a strong-buy rating to a buy rating in a research note released on Thursday morning. Other analysts have also issued research reports about the stock. Evercore ISI upgraded shares of Alkermes from an in-line rating to an outperform rating in a research report on Tuesday, […]

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Alkermes plc (NASDAQ:ALKS), Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) and ImmunoGen, Inc. […]

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.